Document:

Non-Employee Director Compensation Summary

 Exhibit 10.17 
 Non-Employee Director Compensation Summary 
 CuraGen Corporation’s (the “Company”) non-employee
directors are currently: (i) Vincent T. DeVita Jr., M.D.; (ii) John H. Forsgren; (iii) James J. Noble, M.A., F.C.A.; (iv) Robert E. Patricelli; and (v) Patrick J. Zenner. The compensation structure for the Company’s
non-employee directors is as follows: 
 Grant of Options Upon Appointment 
 Each non-employee director will automatically receive an option to purchase 30,000 shares of the Company’s common stock upon appointment to the Company’s Board of Directors (the “Board”). These
options will vest 1/3 upon grant, 1/3 upon the first anniversary of the date of grant, and 1/3 upon the second anniversary of the date of grant (vesting will be accelerated upon a 50% or greater change in control of the Company.) 
 Grant of Additional Stock Options 
 Each non-employee director
who continues to serve on the Board will automatically receive an option to purchase 15,000 shares of the Company’s common stock, granted in conjunction with each year’s Annual Meeting, such option vesting immediately. 
 The Non-Executive Chairman of the Board will receive an option to purchase 7,500 shares of the Company’s common stock, granted in conjunction with each year’s
Annual Meeting (or granted on the date of appointment to the position and prorated for the first fiscal year of appointment, the fiscal year ending with the date of the next regularly scheduled Annual Meeting), such option vesting immediately.

 The Audit Committee Chair will receive an option to purchase 5,000 shares of the Company’s common stock, granted in conjunction with each year’s
Annual Meeting (or granted on the date of appointment to the position and prorated for the first fiscal year of appointment, the fiscal year ending with the date of the next regularly scheduled Annual Meeting), such option vesting immediately.

 The Compensation Committee Chair and the Nominating & Governance Committee Chair will receive an option to purchase 2,500 shares of the
Company’s common stock, granted in conjunction with each year’s Annual Meeting (or granted on the date of appointment to the position and prorated for the first fiscal year of appointment, the fiscal year ending with the date of the next
regularly scheduled Annual Meeting), such option vesting immediately. 
 Payment of Fees: Reimbursement of Travel and Other Expenses

 In addition to the above mentioned stock option grants, each non-employee director will receive an annual retainer of $20,000 for his service on
the Board during 2009. This retainer will be prorated for any non-employee director who serves for only part of the year. Additional amounts will be paid to the non-employee directors during 2009 as follows: 
  

				
	 Position
	  	Additional
Fees
	 Non-Executive Chairman of the Board - Retainer
	  	$	30,000
	 Audit Committee Chair - Retainer
	  	$	15,000
	 Compensation Committee Chair - Retainer
	  	$	10,000
	 Nominating & Governance Committee Chair - Retainer
	  	$	10,000
	 Board meeting fee - regular meeting
	  	$	1,500
	 Board meeting fee - telephonic meeting
	  	$	750
	 Audit Committee meeting - Each member
	  	$	1,250
	 Compensation Committee meeting - Each member
	  	$	1,000
	 Nominating & Governance meeting - Each member
	  	$	1,000
	 Audit Committee telephonic meeting - Each member
	  	$	1,000

				
	 Position
	  	Additional
Fees
	 Compensation Committee telephonic meeting - Each member
	  	$	750
	 Nominating & Governance telephonic meeting - Each member
	  	$	750
	 Per diem for additional work performed on site, in support of Board and/or Committee responsibilities
	  	 	Waived for 2009

 All retainer amounts will be paid quarterly during the fiscal year. Non-employee directors also receive
reimbursement for reasonable travel and other expenses in connection with attending Board and committee meetings during the fiscal year.Amendment to Employment Agreement - Paul M. Finigan

 Exhibit 10.35 
 

 
 February 23, 2009 
 Mr. Paul M. Finigan 
 Executive Vice President & 
 General Counsel 
 CuraGen Corporation 
 322 East Main Street 
 Branford, CT 06405 
  

	Re:	Amendment to Employment Agreement 

 Dear Mr. Finigan: 
 You and CuraGen Corporation (“CuraGen”) are parties to an Employment Agreement, dated September 1, 2006 (the “Employment Agreement”), which
outlines the terms and conditions of your employment with CuraGen. In light of recent tax legislation under Section 409A of the Internal Revenue Code (“Section 409A”), you and CuraGen mutually desire to amend certain provisions of the
Employment Agreement as set forth below: 
 1. Section 11(E)  
 Section 11(E) of the Employment Agreement shall be deleted in its entirety and replaced with the following: 
 All payments and benefits set forth in Sections 11(B)-(D) are contingent on Executive’s execution
(without revocation) of a separation agreement that is in a form acceptable to the Company and contains a full waiver and release of claims against the Company (the “Release”), within twenty-one (21) days of the date of the
Executive’s termination of employment (on which date the separation agreement will be provided to the Executive). The payments and benefits set forth in Sections 11(B)-(D) shall commence on the 30th day following the Executive’s termination of employment, subject to the receipt of the Release and the expiration of any applicable revocation period as of such date.

 2. Section 11(F)  
 Section 11(F) of the
Employment Agreement shall be deleted in its entirety and replaced with the following: 
 (i) Subject to this Section 11(F), severance payments and
benefits payable to Executive under the Employment Agreement shall begin only upon the date of Executive’s “separation 

 
from service” (determined as set forth below) which occurs on or after the termination of Executive’s service with CuraGen. The following rules
shall apply with respect to distribution of the severance payments and benefits, if any, to be provided to Executive under the Employment Agreement, as applicable: 
 (1) It is intended that each installment of the severance payments and benefits provided under the Employment Agreement shall be treated as a separate “payment” for purposes of Section 409A. Neither
CuraGen nor Executive shall have the right to accelerate or defer the delivery of any such severance payments except to the extent specifically permitted or required by Section 409A. 
 (2) If, as of the date of Executive’s “separation from service” from CuraGen, Executive is not a “specified employee” (within the
meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in the Employment Agreement. 
 (3) If, as of the date of Executive’s “separation from service” from CuraGen, Executive is a “specified employee” (within the meaning of Section 409A), then: 
 (a) Each installment of the severance payments and benefits due under the Employment Agreement that, in accordance with the dates and terms set forth
herein, will in all circumstances, regardless of when Executive’s separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of
Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A; and 
 (b) Each installment of the
severance payments and benefits due under the Employment Agreement that is not described in Section 11(F)(i)(3)(a) and that would, absent this subsection, be paid within the six-month period following Executive’s “separation from
service” from CuraGen shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, Executive’s death), with any such installments that are required to be delayed being accumulated
during the six-month period and paid in a lump sum on the date that is six months and one day following Executive’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth
herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide
for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury
Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of Executive’s second taxable year following the taxable year in which the separation from service occurs. 

 (ii) The determination of whether and when Executive’s separation from service from CuraGen has occurred shall be
made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). 
 (iii) All reimbursements and
in-kind benefits provided under the Employment Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A. 
 3. Section 14(H)  
 The following sentence shall be added to the
end of Section 14(H) of the Employment Agreement: 
 To the extent that the total payments to the Executive are reduced pursuant to the preceding
sentence, such payments shall be reduced in the following order: accelerated vesting of stock options, then accelerated vesting of restricted stock, then cash severance, then benefits. 
 Except as specifically provided herein, all other terms of the Employment Agreement shall remain in full force and effect. If the terms of this amendment are acceptable to you, please sign and return the copy of this
amendment enclosed for that purpose to Nathalie Richard, Director of Human Resources. 
 Sincerely, 
 CuraGen Corporation 
  

			
	By:	 	 /s/    Timothy M. Shannon

	Title:	 	Pres & CEO

 The foregoing correctly sets forth the terms of my continued employment with CuraGen Corporation. I am not relying
on any representations other than as set out in the Employment Agreement and the amendment thereto set forth above. I have been given a reasonable amount of time to consider this amendment and to consult an attorney and/or advisor of my choosing. I
have carefully read this amendment, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign my name of my own free act. 
  

			
	Name:	 	 /s/    Paul M. Finigan

		
	Date:	 	 March 5, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]